Metabolic Dysfunction-associated Fatty Liver Disease
13
4
5
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 13 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (13)
Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD
An Observational Clinical Study on the Association of Intestinal Ruminococcus Gnavus and Its Derived Biogenic Amines With Metabolic Dysfunction-associated Fatty Liver Disease
CPET-based HIIT for MAFLD
Efficacy and Safety of Calculus Bovis Sativus in Adults With MAFLD
Intermittent Fasting and Metabolic Dysfunction Associated Fatty Liver Disease
Evaluate the Effect of Synbiotics on MAFLD
Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study
Thyroid Dysfunction and Its Association With Metabolic Dysfunction-Associated Fatty Liver Disease
Effect of L-citrulline and HIIT on Arterial Stiffness, Body Composition, and Lipid Profile in Adolescents with Steatosis Associated with Metabolic Dysfunction (MASLD)
Positive Association of US-FLI With the Severity of CAD
Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies
The Potential Value and Impact of Diagnostic Biomarkers for MAFLD Using Machine Learning Methods
NMR-based Metabolic Profiling Identifies High Risk of MAFLD Patients With Advanced Fibrosis